A new experimental drug is showing remarkable promise for children with Dravet syndrome, a severe genetic form of epilepsy.
An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.
An experimental drug reduced seizures by up to 91% in children with Dravet syndrome. | Drug Discovery And Development ...
Families say the groundbreaking medicine is transforming the lives of children with Dravet syndrome.
Clinical Trials Arena on MSN
Analysts tout market potential of Xenon’s epilepsy drug on Phase III win
Analysts are encouraged by azetukalner’s differentiated MoA and efficacy in epilepsy, as well as the lack of titration needed when prescribing the drug.
Preliminary trials into Zorevunersen find drug to be safe and well tolerated by those with Dravet syndrome ...
Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...
DelveInsight forecasts a rise in the drug-resistant epilepsy market from 2025 to 2034, driven by higher prevalence, improved diagnosis, treatment advances, aging demographics, increased awareness, and ...
Researchers identify prochlorperazine as a potential new treatment for temporal lobe epilepsy by restoring the KCC2 chloride ...
Researchers have discovered that mutations in the FOXJ3 gene act as a "master switch" failure, disrupting how the brain ...
Many patients suffer from epilepsy that cannot be controlled by current medications. Surgical removal of epileptogenic brain regions is effective in only about half of cases, and not all patients are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results